Childhood cancer treatments may increase obesity risk later
the ONA take:
According to a new study published online early in the journal Cancer, researchers have found that certain treatments used to treat children with cancer may increase their risk for obesity later in life.
For the study, researchers analyzed data from nearly 2,000 cancer survivors previously treated for their disease at St. Jude Children's Research Hospital in Memphis, Tennessee, who had been diagnosed with cancer at least 10 years ago. Results showed that 47% of survivors who had received cranial radiation were obese versus 29.4% of those who had not received cranial radiation.
Researchers found that patients who were treated with cranial radiation plus glucocorticoids, such as prednisone and dexamethasone, had an increased likelihood of obesity. Patients who were younger at the time of diagnosis also had an increased risk for obesity.
The findings may help health care providers identify cancer survivors who are more likely to become obese and guide treatment selection in order to minimize long-term complications.
Certain treatments used to treat children with cancer may increase their risk for obesity later in life.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|